Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 176Colorectal Neoplasms 153Rectal Neoplasms 122Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Gallbladder Neoplasms 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

Trastuzumab 2pyrotinib 1pertuzumab 1Vinorelbine 1Lapatinib 1Docetaxel 1Carboplatin 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Breast Cancer × Capecitabine × Clear all
NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Sun Yat-sen University

Phase 2 Completed
159 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡